ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 12, 2013--
BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff,
former CEO and Chairman of Gen-Probe Inc., has been appointed to its
Board of Directors.
“We are pleased to welcome an accomplished healthcare executive of
Hank's caliber to BioTime's board,” said Alfred D. Kingsley, Chairman of
the Board of BioTime. “Hank's 43 years of experience in the
pharmaceutical business, including most recently his leadership role in
managing impressive growth at Gen-Probe over a 15-year period should
prove valuable as BioTime continues to pursue multiple growth
“BioTime is a leading company in the emerging field of Regenerative
Medicine,” said Mr. Nordhoff. “I am pleased to be joining BioTime at
this important juncture, as the company moves towards translating a
magnificent array of technologies into products, and then introducing
those products into the marketplace to alleviate suffering and cure
Mr. Nordhoff is the former CEO and Chairman of Gen-Probe, Inc., a
leading molecular diagnostics company which was acquired in 2012 in an
all-cash transaction that valued the company at $3.72 billion. Under Mr.
Nordhoff's leadership, Gen-Probe introduced numerous innovative
diagnostic products to test for a host of infectious disease-causing
viruses and bacteria, screening products to help identify compatible
transplant matches, and instruments and assays to screen donated blood
for diseases. Prior to joining Gen-Probe in 1994, Mr. Nordhoff served as
President and CEO of TargeTech, Inc., a gene therapy and antisense
company that merged into the Immune Response Corporation; as President
and CEO of American Biogenetic Sciences, Inc., a monoclonal antibody
company that went public during his tenure; as Vice President of
Acquisitions and Business Development at Sterling Drug Inc.; and in a
number of senior positions at Pfizer Inc. in Brussels, Seoul, Tokyo and
New York. Mr. Nordhoff holds a Master's in Business Administration from
Columbia University and a Bachelor of Arts in International Relations
and Political Economy from Johns Hopkins University.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem™
cell lines, HyStem® hydrogels, culture media, and differentiation kits.
BioTime is developing Renevia™ (formerly known as HyStem®-Rx), a
biocompatible, implantable hyaluronan and collagen-based matrix for cell
delivery in human clinical applications. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high
unmet medical need. BioTime's majority owned subsidiary Cell Cure
Neurosciences Ltd. is developing therapeutic products derived from stem
cells for the treatment of retinal and neural degenerative diseases.
BioTime's subsidiary OrthoCyte Corporation is developing therapeutic
applications of stem cells to treat orthopedic diseases and injuries.
Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards®, the leading human gene
database, as part of an integrated database suite that also includes the
LifeMap Discovery™ database of embryonic development, stem cell research
and regenerative medicine, and MalaCards, the human disease database.
LifeMap Sciences also markets BioTime research products and PanDaTox, an
innovative, recently developed, searchable database that can aid in the
discovery of new antibiotics and biotechnologically beneficial products.
Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire
the stem cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment for
the development of new therapeutic products for regenerative medicine.
BioTime's lead product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corporation under exclusive licensing
agreements. Additional information about BioTime can be found on the web
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
Source: BioTime, Inc.
Robert Peabody, 510-521-3390, ext 302
Sr. VP &
Segall, 510-521-3390, ext 301